Inspite of achieving an entire response with optimum induction therapy, minimal residual disease generally persists, necessitating consolidation therapy to mitigate the risk of relapse by doing away with residual condition. In sufferers who may have obtained 7+3 induction therapy, consolidation therapy is initiated with significant-dose cytarabine